[Glycoprotein 2b3a inhibitors for acute coronary syndromes: what the trials tell us].


Glycoprotein 2b3a inhibitors represent a promising class of antiplatelet medications. Their use in acute coronary syndromes and in patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials, including tens of thousands of patients. These trials examined their efficacy, the difference between the… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics